Eyenovia

82 articles with Eyenovia

• Eyenovia Reports First Quarter 2022 Financial Results

  5/12/2022

  Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial and operating results for the first quarter ended March 31, 2022.

• Eyenovia to Report First Quarter 2022 Results on Thursday, May 12

  5/5/2022

  Eyenovia, Inc. announced that the Company will release financial results for the first quarter ended March 31, 2022 on Thursday, May 12, 2022, after the markets close.

• Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

  4/20/2022

  Eyenovia, Inc. today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer, will deliver a presentation at Eyecelerator, which is being held on Thursday, April 21 in Washington, DC.

• Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

  4/19/2022

  Eyenovia, Inc. today announced that the Company will present an ePoster at the American Society of Cataract and Refractive Surgery Annual Meeting, which is being held April 23-26 in Washington, D.C.

• Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

  3/28/2022

  Eyenovia, Inc. announced its financial results for the fourth quarter ended December 31, 2021.

• Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28Company to host an investor conference call and webcast at 4:30pm ET on that day

  3/21/2022

  Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022, after the markets close.

• Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

  3/15/2022

  Eyenovia, Inc. (NASDAQ: EYEN), today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from Latanoprost+Benzalkonium Chloride (BAK) treatment administered via Optejet versus Latanoprost+BAK administered via standard eye drops.

• Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.

  3/4/2022

  Eyenovia, Inc. today announced that the company has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd.

• Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission No additional clinical work required; NDA resubmission anticipated in Q3 2022

  2/8/2022

  Eyenovia, Inc. today announced that the company successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) related to the refiling of the NDA for MydCombi.

• Eyenovia Announces Changes to Board of Directors

  2/7/2022

  Eyenovia, Inc. today announced changes to its Board of Directors.

• Eyenovia Reports Third Quarter 2021 Financial Results

  11/10/2021

  Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial results for the third quarter ended September 30, 2021.

• Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

  11/8/2021

  Eyenovia, Inc. today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia, will participate in a panel discussion on myopia at the Eyecelerator@AAO 2021 Meeting, which is being held on Thursday, November 11, 2021

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

  11/5/2021

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021, after the market close.

• Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

  11/4/2021

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the third quarter ended September 30, 2021 on Thursday, November 11, 2021, after the market close.

• Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

  11/4/2021

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the first patient has been enrolled in the Company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in near vision, known as VISION-2.

• 

  FDA Action Alert: Pfizer-BioNTech, Oncopeptides, Eyenovia, ANI and More

  10/25/2021

  The U.S. FDA has a busy period at the end of October heading into the first week of November.

• Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

  10/25/2021

  Eyenovia, Inc. (NASDAQ: EYEN), today announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product by the U.S. Food and Drug Administration (FDA) in a Complete Response Letter (CRL) for the company’s new drug application (NDA) received on October 22, 2021.

• Eyenovia Reports Second Quarter 2021 Financial Results

  8/11/2021

  Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial and operating results for the second quarter ended June 30, 2021.

• Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11

  8/4/2021

  Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced that the Company will release financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021, after the market close.